Estimating breast cancer mortality reduction and overdiagnosis due to screening for different strategies in the United Kingdom.

Targeted Cancer Screening in Average-Risk Individuals. Am J Prev Med (2015) 0.79

Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation. BMC Cancer (2015) 0.77

The BUGS project: Evolution, critique and future directions. Stat Med (2009) 11.19

Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ (2000) 5.20

Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol (2007) 3.49

The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43

Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res (2002) 3.07

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91

The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. Eur J Cancer (2002) 2.28

Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer (2003) 2.26

Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer (2007) 1.94

Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev (2011) 1.77

PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res (2010) 1.55

Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen (2012) 1.50

A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen (1999) 1.40

Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer (2008) 1.35

Radiation doses received in the UK Breast Screening Programme in 2001 and 2002. Br J Radiol (2005) 1.32

Comparison of 1- and 2-year screening intervals for women undergoing screening mammography. Br J Cancer (2005) 1.16

Overdiagnosis in breast cancer: design and methods of estimation in observational studies. Prev Med (2011) 1.12

Radiation doses in the UK trial of breast screening in women aged 40-48 years. Br J Radiol (2002) 1.05

Markov models of breast tumor progression: some age-specific results. J Natl Cancer Inst Monogr (1997) 0.96

Explaining the difference in prognosis between screen-detected and symptomatic breast cancers. Br J Cancer (2011) 0.93

Interval cancers and sensitivity in the screening centres of the UK trial of early detection of breast cancer. Eur J Cancer (1993) 0.92

The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. J Med Screen (2011) 0.87

Long-term survival of women with breast cancer in New South Wales. Eur J Cancer (2003) 0.87

Prediction of higher mortality reduction for the UK Breast Screening Frequency Trial: a model-based approach on screening intervals. Br J Cancer (2011) 0.85

Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Res (2012) 0.82